Guangxi Medical University Cancer Hospital
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China24 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers | Advanced Solid Tumor | Enrolling by invitation | Phase 1 | 2026-09-21 | NCT06169579 | |
| A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors | Solid Tumor Malignancies | Recruiting | Phase 1 | 2026-09-16 | NCT07071090 | |
| A Phase II Trial of LM103 in Advanced Melanoma | Advanced Melanoma | Recruiting | Phase 2 | 2026-08-31 | NCT07310784 | |
| A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 2 / Phase 3 | 2026-08-26 | NCT06891833 | |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT06680921 | |
| PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-07-29 | NCT06419621 | |
| Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma | Nasopharyngeal Cancinoma (NPC) | Recruiting | Phase 2 | 2026-07-23 | NCT07528183 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors | Advanced Cancer; Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-05-22 | NCT06656390 | |
| A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors | Solid Malignancies | Recruiting | Phase 1 | 2026-05-08 | NCT06725381 | |
| Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | Immune-related Pneumonia; Radiation-induced Lung Injury | Recruiting | Phase 2 / Phase 3 | 2026-04-22 | NCT07388680 | |
| Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-17 | NCT07496229 | |
| A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-04-13 | NCT06564324 | |
| A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 | 2026-03-13 | NCT06008288 | |
| A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-02-10 | NCT06064812 | |
| 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma | Disease Attributes, Disease Progression, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 3 | 2026-01-09 | NCT07328854 | |
| ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-01-08 | NCT07327034 | |
| A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-01-02 | NCT07093814 | |
| A Clinical Study of YL205 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-12-23 | NCT06459973 | |
| A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | Disease Attributes, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Recurrence, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 1 / Phase 2 | 2025-12-02 | NCT07258979 | |
| A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 2 | 2025-11-24 | NCT06839066 | |
| A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations | Advanced Solid Tumors; KRAS G12D Mutations | Recruiting | Phase 1 / Phase 2 | 2025-11-20 | NCT06500676 | |
| A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation | KRAS G12D Mutation | Recruiting | Phase 1 / Phase 2 | 2025-10-30 | NCT06667544 | |
| AMT-116 in Patients with Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-01-17 | NCT06782334 | |
| ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2024-08-20 | NCT06007729 |